Taconic Capital Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Taconic Capital Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-200,000	Closed	-$9K	–	40
2016 Q2	$9K	Buy	200,000 +100,000	+100%	+$5.32M	﹤0.01%	50
2016 Q1	$5.35M	Sell	100,000 -100,000	-50%	-$5.87M	0.15%	47
2015 Q4	$724K	Buy	200,000 +150,000	+300%	+$9.27M	0.02%	61
2015 Q3	$102K	Buy	+50,000	New	+$3.24M	﹤0.01%	70

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Taconic Capital Advisors's TEVA Position: Q4 2016 in Review

Taconic Capital Advisors sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 100,000 shares — an estimated $4.6M sold.

Taconic Capital Advisors first reported a position in TEVA in Q3 2015 and held it in 5 quarters. The position peaked at $33M in Q3 2015. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Taconic Capital Advisors reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Taconic Capital Advisors sold 100,000 Teva Pharmaceuticals shares in Q4 2016, an estimated $4.6M.
Taconic Capital Advisors first reported a position in Teva Pharmaceuticals in Q3 2015 and held it in 5 quarters.
Taconic Capital Advisors's Teva Pharmaceuticals position peaked at $33M in Q3 2015.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Taconic Capital Advisors's 13F filing for Q4 2016, filed 13 Feb 2017.